Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 1105 results for "ranbaxy"

Buy Ranbaxy Labs 780 Call: VK Sharma

VK Sharma of HDFC Securities recommends buying Ranbaxy Labs 780 Call. Money Control, 14 hours ago
Buy Lupin 1600 Call, Ranbaxy 740 Call: VK Sharma Money Control, 4 weeks ago
Buy Lupin 1500 call, Ranbaxy 700 Call: VK Sharma Money Control, 1 month ago

87 images for ranbaxy

India Infoline, 1 day ago
NDTV Profit, 2 days ago
Livemint.com, 2 days ago
Financial Express, 2 days ago
Money Control, 2 days ago
Lawyer Herald, 5 days ago
Yahoo! News, 5 days ago
Livemint.com, 5 days ago
Reuters, 5 days ago
DNA India, 2 days ago
Reuters

U.S. Judge Denies Ranbaxy Bid to Reinstate Approvals for Valcyte, Nexium Copies

Reuters Health Information By Reuters Staff March03,2015 MUMBAI (Reuters) - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn ...
 Diabetes Care1 day ago US Judge Blocks Ranbaxy Launch Bid  Pharmaceutical Executive2 days ago US judge denies Ranbaxy to launch Valcyte, Nexium copy  Economic Times5 days ago US judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies  Smart Investor5 days ago
[x]  

Sun Pharma, Ranbaxy vault

Intraday volatility continued as key benchmark indices retained positive zone in early afternoon trade. The market breadth indicating the overall health of the market was negative. The Reserve Bank of India (RBI) surprised financial markets today, ...
 Business Standard1 day ago Sun Pharma, Ranbaxy advance after CCI nod for merger  Business Standard2 months ago Lupin hits record high as RBI raises FII investment ceiling  Business Standard India2 weeks ago

Suzlon, APSEZ and Ranbaxy Laboratories to see some action today

Indian wind turbine maker Suzlon Energy expects to turn profitable in the fiscal year starting on April 1 after six years of losses, helped by a surge in demand for renewable energy and a reduction in its debt. Suzlon is likely to exit the debt ...
 Indian-Commodity1 day ago

Sun Pharma, Ranbaxy vault

This page uses frames, but your browser doesn't
 Capital Market1 day ago
Livemint.com

Ranbaxy loses approvals, right to sell two drugs in US

A US court has upheld the decision by the US Food and Drug Administration (FDA) to cancel the approvals given to Ranbaxy to sell and market the generic versions of AstraZeneca's heartburn medicine Nexium and Roche's anti-viral medicine Valcyte. In ...
 Hindu Business Line2 days ago Ranbaxy loses appeal on approvals, exclusivity of 2 drugs in US  Livemint.com2 days ago Ranbaxy loses approvals of 2 drugs in U.S.  The Hindu2 days ago Ranbaxy loses US appeal on Nexium, Valcyte generics  Hindu Business Line2 days ago
[x]  
Business Standard

Udbhav Ganjoo quits Ranbaxy, may join Mylan

Read more on: Health/Medical/Pharmaceuticals | Mylan Inc. | Ranbaxy Laboratories | Udbhav Ganjoo Udbhav Ganjoo, the global Head of Human Resources Ranbaxy Laboratories, has resigned from the company and may join multinational ...
 EHealth Magazine2 days ago Ranbaxy's global HR head Udbhav Ganjoo quits  Business Standard3 days ago Ranbaxy Lab global HR head Udbhav Ganjoo quits  India Infoline3 days ago
[x]  
The Telegraph

US court quashes Ranbaxy's plea against FDA on Nexium, Valcyte generic

A US court has dismissed a plea by Ranbaxy challenging the American drug regulator's move to revoke the 180-day exclusivity granted to the Indian pharma major for selling low-cost copies of two blockbuster drugs—AstraZeneca's Nexium and Roche AG's ...
 VC Circle2 days ago Ranbaxy suffers fresh jolt  The Telegraph1 month ago 'Ranbaxy's Nexium generic loss may up Cipla's EPS 3-5%'  Money Control1 month ago

DoP turns down Ranbaxy's review application on gentamicin, renitidine and dexamethasone injections

The department of pharmaceuticals (DoP) has turned down the review application filed by Ranbaxy Laboratories against the fixation/revision of ceiling prices of gentamicin injection 40 mg/ml, renitidine injection 25 mg/ml and dexamethasone injection ...
 PharmaBiz3 days ago DoP rejects Ranbaxy's review application on Histec EVT tabs & Fucibet cream in 15 gm aluminium tube  PharmaBiz4 weeks ago
Marketing-interactive.com

Havas Media Group India wins digital mandate of Ranbaxy's consumer healthcare brands

The win comes on the back of a multi-agency pitch, which included the incumbent as well as all leading digital agencies BestMediaInfo Bureau | Delhi | February 26, 2015 Havas Media Group India has been assigned the digital marketing mandate ...
 Best Media Info1 week ago Ranbaxy selects Havas Media Group for its digital account  Marketing-interactive.com6 days ago Havas Media bags digital duties of Ranbaxy's Consumer Healthcare brands  Afaqs1 week ago Havas wins digital mandate of Ranbaxy's consumer healthcare brands  Indian Television1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less